当前位置： SCI文献检索 > MOLECULAR CANCER THERAPEUTICS期刊下所有文献 > Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

Abstract：

:Notch signaling is aberrantly activated in approximately one third of non-small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in preclinical models of NSCLC. Chemosensitivity assays were performed on 14 human NSCLC cell lines. There was significantly greater synergy between BMS-906024 and paclitaxel than BMS-906024 and cisplatin [mean combination index (CI) value, 0.54 and 0.85, respectively, P = 0.01]. On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003). Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group. Knockdown of mutant KRAS increased the synergy between BMS-906024 and paclitaxel in heterozygous KRAS-mutant cell lines. Among KRAS- or BRAF-mutant NSCLC, there was a significant correlation between synergy and mutant or null TP53 status, as well as between synergy and a low H2O2 pathway signature. Exogenous overexpression of activated Notch1 or Notch3 had no effect on the enhanced sensitivity of NSCLC to paclitaxel by BMS-906024. In vivo studies with cell line- and patient-derived lung adenocarcinoma xenografts confirmed enhanced antitumor activity for BMS-906024 plus paclitaxel versus either drug alone via decreased cell proliferation and increased apoptosis. These results show that BMS-906024 sensitizes NSCLC to paclitaxel and that wild-type KRAS and BRAF status may predict better patient response to the combination therapy. Mol Cancer Ther; 16(12); 2759-69. ©2017 AACR.

journal_name

Mol Cancer Ther

journal_title

Molecular cancer therapeutics

authors

Morgan KM,Fischer BS,Lee FY,Shah JJ,Bertino JR,Rosenfeld J,Singh A,Khiabanian H,Pine SR

doi

10.1158/1535-7163.MCT-17-0439

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

2759-2769

issue

12

eissn

1535-7163

issn

1538-8514

pii

1535-7163.MCT-17-0439

journal_volume

16

pub_type

杂志文章

相关文献

MOLECULAR CANCER THERAPEUTICS文献大全
  • A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities.

    abstract：:We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative activity against nine cancer cell lines in vitro. Flow cytometric analyses showed that the compound caused G2-M arrest, which occurred mainly at the mitotic phase. In addition, immunofluores...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0254

    authors： Li PK,Pandit B,Sackett DL,Hu Z,Zink J,Zhi J,Freeman D,Robey RW,Werbovetz K,Lewis A,Li C

    更新日期：2006-02-01 00:00:00

  • Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.

    abstract：:The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines. 4-Oxo-4-HPR and 4-HPR have different mechanisms of action because 4-oxo-4-HPR, unl...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0798

    authors： Appierto V,Tiberio P,Cavadini E,Casalini P,Cappelletti G,Formelli F

    更新日期：2009-12-01 00:00:00

  • Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

    abstract：PURPOSE:Expression of the type 1 insulin-like growth factor receptor (IGF1R) confers adverse prognosis in clear cell renal cell cancer (CC-RCC). We recently showed that IGF1R expression is inhibited by the von Hippel-Lindau (VHL) tumor suppressor, and the IGF1R is up-regulated in CC-RCC, in which VHL is frequently inac...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0101

    authors： Yuen JS,Akkaya E,Wang Y,Takiguchi M,Peak S,Sullivan M,Protheroe AS,Macaulay VM

    更新日期：2009-06-01 00:00:00

  • Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.

    abstract：:The androgen receptor (AR) is a key driver and therapeutic target in androgen-sensitive prostate cancer, castration-resistant prostate cancer (CRPC), and CRPC resistant to abiraterone and enzalutamide, two second-generation inhibitors of AR signaling. Because current AR inhibitors target a functioning C-terminal ligan...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0432

    authors： Dong J,Wu Z,Wang D,Pascal LE,Nelson JB,Wipf P,Wang Z

    更新日期：2019-01-01 00:00:00

  • Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines.

    abstract：:The serine/threonine kinase AKT/PKB plays a critical role in cancer and represents a rational target for therapy. Although efforts in targeting AKT pathway have accelerated in recent years, relatively few small molecule inhibitors of AKT have been reported. The development of selective AKT inhibitors is further challe...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0211

    authors： Toral-Barza L,Zhang WG,Huang X,McDonald LA,Salaski EJ,Barbieri LR,Ding WD,Krishnamurthy G,Hu YB,Lucas J,Bernan VS,Cai P,Levin JI,Mansour TS,Gibbons JJ,Abraham RT,Yu K

    更新日期：2007-11-01 00:00:00

  • ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice.

    abstract：:Anti-HER2 monoclonal antibodies (mAb) have been shown to reduce tumor size and increase survival in patients with breast cancer, but they are ineffective against brain metastases due to poor brain penetration. In previous studies, we identified a peptide, known as Angiopep-2 (An2), which crosses the blood-brain barrie...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0399

    authors： Regina A,Demeule M,Tripathy S,Lord-Dufour S,Currie JC,Iddir M,Annabi B,Castaigne JP,Lachowicz JE

    更新日期：2015-01-01 00:00:00

  • Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease.

    abstract：:The development of new drugs against cancer requires established cell lines. They are needed for in vitro studies to identify candidate drugs and in xenograft models to measure drug efficacy in vivo. Specific criteria need to be fulfilled by cell lines used in the evaluation of potential novel therapeutic agents. It i...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Kees UR,Ford J,Watson M,Murch A,Ringńer M,Walker RL,Meltzer P

    更新日期：2003-07-01 00:00:00

  • Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.

    abstract：:Genital human papillomavirus (HPV) infection is the primary cause of cervical cancer in women. Although the HPV recombinant L1 protein was recently licensed as an available vaccine, it has numerous shortcomings. New vaccination strategies should be considered. To enable the design of a prophylactic and therapeutic low...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-2015

    authors： Bian T,Wang Y,Lu Z,Ye Z,Zhao L,Ren J,Zhang H,Ruan L,Tian H

    更新日期：2008-05-01 00:00:00

  • RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

    abstract：:Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role of receptor act...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-20-0378

    authors： Wang H,Ashton R,Hensel JA,Lee JH,Khattar V,Wang Y,Deshane JS,Ponnazhagan S

    更新日期：2020-12-01 00:00:00

  • 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.

    abstract：:Interference with endothelial cell metabolism is a promising, yet unexploited strategy for angiogenesis inhibition. We reported that the glucose analogue 2-deoxy-D-glucose (2-DG) inhibits angiogenesis at significantly lower concentrations than those required for tumor cytotoxicity. Here, we found that hypersensitivity...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0315

    authors： Kovács K,Decatur C,Toro M,Pham DG,Liu H,Jing Y,Murray TG,Lampidis TJ,Merchan JR

    更新日期：2016-02-01 00:00:00

  • Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.

    abstract：:The present studies have determined whether interactions between the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat; Zolinza) occur in breast cancer cells. MDA-MB-231 and MCF7 cells were treated with flavopiridol (25-100 nmol/L) an...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0561

    authors： Mitchell C,Park MA,Zhang G,Yacoub A,Curiel DT,Fisher PB,Roberts JD,Grant S,Dent P

    更新日期：2007-12-01 00:00:00

  • Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.

    abstract：:The standard treatment for advanced, androgen-responsive prostate cancer is androgen deprivation therapy with or without a nonsteroidal antiandrogen, such as bicalutamide. Although maximal androgen blockade exhibits favorable responses in the majority of patients, prostate cancer eventually progresses to an androgen-r...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0823

    authors： Feng S,Tang Q,Sun M,Chun JY,Evans CP,Gao AC

    更新日期：2009-03-01 00:00:00

  • The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.

    abstract：:Proteasome inhibitors are potent inducers of apoptosis in isolated lymphocytes from patients with chronic lymphocytic leukemia (CLL). However, the reversible proteasome inhibitor bortezomib (PS-341; Velcade) did not display substantial antitumor activity in CLL patients. Here, we compared the effects of bortezomib and...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0066

    authors： Ruiz S,Krupnik Y,Keating M,Chandra J,Palladino M,McConkey D

    更新日期：2006-07-01 00:00:00

  • Monoclonal Antibody Targeting Sialyl-di-Lewisa-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential.

    abstract：:Tumor glycans constitute attractive targets for therapeutic antibodies. The sialylated glycocalyx plays a prominent role in cancer progression and immune evasion. Here, we describe the characterization of the mAb, FG129, which targets tumor-associated sialylated glycan, and demonstrate its potential for multimodal can...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-0221

    authors： Tivadar ST,McIntosh RS,Chua JX,Moss R,Parsons T,Zaitoun AM,Madhusudan S,Durrant LG,Vankemmelbeke M

    更新日期：2020-03-01 00:00:00

  • Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

    abstract：:RECQL1, a key member of the RecQ family of DNA helicases, is required for DNA replication and DNA repair. Two recent studies have shown that germline RECQL1 mutations are associated with increased breast cancer susceptibility. Whether altered RECQL1 expression has clinicopathologic significance in sporadic breast canc...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0290

    authors： Arora A,Parvathaneni S,Aleskandarany MA,Agarwal D,Ali R,Abdel-Fatah T,Green AR,Ball GR,Rakha EA,Ellis IO,Sharma S,Madhusudan S

    更新日期：2017-01-01 00:00:00

  • Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

    abstract：:The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is known to be activated by radiation. The mammalian target of rapamycin (mTOR) is downstream of Akt, and we investigated the effects of radiation on Akt/mTOR signaling in breast cancer cell models. RAD001 (everolimus), a potent derivative of the mTOR inhibitor rapa...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0400

    authors： Albert JM,Kim KW,Cao C,Lu B

    更新日期：2006-05-01 00:00:00

  • SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

    abstract：:Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical and clinical studies but at least two ligands mediate the effect...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Hjelmeland MD,Hjelmeland AB,Sathornsumetee S,Reese ED,Herbstreith MH,Laping NJ,Friedman HS,Bigner DD,Wang XF,Rich JN

    更新日期：2004-06-01 00:00:00

  • Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

    abstract：:To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on three human (A2780, SKOV3ip1, and HeyA8) and a mouse (ID8) ovar...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0074

    authors： Huang Y,Lichtenberger LM,Taylor M,Bottsford-Miller JN,Haemmerle M,Wagner MJ,Lyons Y,Pradeep S,Hu W,Previs RA,Hansen JM,Fang D,Dorniak PL,Filant J,Dial EJ,Shen F,Hatakeyama H,Sood AK

    更新日期：2016-12-01 00:00:00

  • Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.

    abstract：:Hormone refractory metastatic prostate cancer is a deadly disease that currently lacks curative treatments. Conditionally replicating adenoviruses (CRAds) are promising new agents against cancer due to their innate capability to cause oncolysis of tumor cells. Their antitumor effect is determined in part by their capa...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0403

    authors： Rajecki M,Kanerva A,Stenman UH,Tenhunen M,Kangasniemi L,Särkioja M,Ala-Opas MY,Alfthan H,Sankila A,Rintala E,Desmond RA,Hakkarainen T,Hemminki A

    更新日期：2007-02-01 00:00:00

  • IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

    abstract：:Antiestrogens are effective therapies for the management of many estrogen receptor-alpha (ER)-positive breast cancers. Nonetheless, both de novo and acquired resistance occur and remain major problems in the clinical setting. IFNgamma is an inflammatory cytokine that induces the expression and function of IFN regulato...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-1169

    authors： Ning Y,Riggins RB,Mulla JE,Chung H,Zwart A,Clarke R

    更新日期：2010-05-01 00:00:00

  • Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme.

    abstract：:The difficulties associated with treatment of malignant brain tumors are well documented. For example, local infiltration of high-grade astrocytomas prevents the complete resection of all malignant cells. It is, therefore, critical to develop delivery systems for chemotherapeutic agents that ablate individual cancer c...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0480

    authors： Madhankumar AB,Slagle-Webb B,Mintz A,Sheehan JM,Connor JR

    更新日期：2006-12-01 00:00:00

  • Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2.

    abstract：:Enhancer of zester homolog 2 (EZH2), a histone lysine methyltransferase and the catalytic component of polycomb repressive complex 2, has been extensively investigated as a chromatin regulator and a transcriptional suppressor by methylating H3 at lysine 27 (H3K27). EZH2 is upregulated or mutated in most cancers, and i...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-20-0250

    authors： Li Q,Liu KY,Liu Q,Wang G,Jiang W,Meng Q,Yi Y,Yang Y,Wang R,Zhu S,Li C,Wu L,Zhao D,Yan L,Zhang L,Kim JS,Zu X,Kozielski AJ,Qian W,Chang JC,Patnaik A,Chen K,Cao Q

    更新日期：2020-10-01 00:00:00

  • V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells.

    abstract：:Fighting metastasis is a major challenge in cancer therapy and novel therapeutic targets and drugs are highly appreciated. Resistance of invasive cells to anoikis, a particular type of apoptosis induced by loss of cell-matrix contact, is a major prerequisite for their metastatic spread. Inducing anoikis in metastatic ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0484

    authors： Schempp CM,von Schwarzenberg K,Schreiner L,Kubisch R,Müller R,Wagner E,Vollmar AM

    更新日期：2014-04-01 00:00:00

  • Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease.

    abstract：:The application of cancer gene therapy has heretofore been restricted to local, or locoregional, neoplastic disease contexts. This is owing to the lack of gene transfer vectors, which embody the requisite target cell selectivity in vivo required for metastatic disease applications. To this end, we have explored novel ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-0768

    authors： Lee M,Lu ZH,Li J,Kashentseva EA,Dmitriev IP,Mendonca SA,Curiel DT

    更新日期：2020-03-01 00:00:00

  • An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities.

    abstract：:Glycosylation is a complex multienzyme-related process that is frequently deregulated in cancer. Aberrant glycosylation can lead to the generation of novel tumor surface-specific glycotopes that can be targeted by antibodies. Murine DS6 mAb (muDS6) was generated from serous ovary adenocarcinoma immunization. It recogn...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-0826

    authors： Nicolazzi C,Caron A,Tellier A,Trombe M,Pinkas J,Payne G,Carrez C,Guérif S,Maguin M,Baffa R,Fassan M,Adam J,Mangatal-Wade L,Blanc V

    更新日期：2020-08-01 00:00:00

  • Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

    abstract：:Histone modification has emerged as a promising approach to cancer therapy. We explored the efficacy of a novel class of histone deacetylase inhibitors in the treatment of malignant gliomas. Treatment of glioma cell lines with two butyric acid derivatives, pivaloylomethyl butyrate (AN-9) and butyroyloxymethyl butyrate...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0087

    authors： Entin-Meer M,Rephaeli A,Yang X,Nudelman A,VandenBerg SR,Haas-Kogan DA

    更新日期：2005-12-01 00:00:00

  • Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

    abstract：:Improved survival for patients with head and neck cancers (HNC) with recurrent and metastatic disease warrants that cancer therapy is specific, with protected delivery of the therapeutic agent to primary and metastatic cancer cells. A further objective should be that downregulation of the intracellular therapy target ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0166

    authors： Unger GM,Kren BT,Korman VL,Kimbrough TG,Vogel RI,Ondrey FG,Trembley JH,Ahmed K

    更新日期：2014-08-01 00:00:00

  • Meeting report on the second targeted tumor therapies.

    abstract：:This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor Therapies and held from April 1-3, 200...

    journal_title：Molecular cancer therapeutics

    pub_type：

    doi：10.1158/1535-7163.MCT-09-0491

    authors： Bachran C,Fuchs H

    更新日期：2010-01-01 00:00:00

  • Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.

    abstract：:Breast cancer resistance to the antiestrogens tamoxifen (OHT) and fulvestrant is accompanied by alterations in both estrogen-dependent and estrogen-independent signaling pathways. Consequently, effective inhibition of both pathways may be necessary to block proliferation of antiestrogen-resistant breast cancer cells. ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-2350

    authors： Long X,Fan M,Bigsby RM,Nephew KP

    更新日期：2008-07-01 00:00:00

  • BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity.

    abstract：:Nucleoside phosphonates are widely used therapeutic agents with a broad spectrum of antiviral activity. However, only a few of them are reported to have antitumor activity. In this study, we show that a tetrahydrofuran phosphonate analogue of guanosine, (-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-ylmethyl) tetrahydr...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Leblond L,Attardo G,Hamelin B,Bouffard DY,Nguyen-Ba N,Gourdeau H

    更新日期：2002-07-01 00:00:00